Introduction
============

Alzheimer's disease (AD) is the most common neurodegenerative disorder, accounting for majority of dementia worldwide ([@B5]). It is characterized by progressive loss in memory and cognitive functions. The hallmark of disease is the presence of senile plaques and neurofibrillary tangles in the brain ([@B65]). The neurodegeneration in AD starts much before the appearance of the first clinical symptoms. The early clinical phase, the amnestic mild cognitive impairment has neuropathological features intermediate between those of normal aging and AD, in which Tau deposits are abundant in the entorhinal cortex and hippocampus. Spreading of high amyloid load and Tau pathology to the entire cortical regions marks the later stages of AD. Deficits in numerous neurotransmitters increase with progression of disease ([@B52]; [@B24]). Pathogenesis of AD is complex and remains elusive. Mutations in different genes like amyloid β-protein precursor (AβPP), presenilin-1 (PS1), presenilin-2 (PS2), and Tau have been identified as genetic determinants for AD ([@B53]). This led to generation of different transgenic models to understand mechanism and pathology of AD. However, sporadic AD, the most common type of the disease, has not been associated with specific gene mutations suggesting genetic models do not faithfully represent all aspects of AD ([@B29]; [@B45]; [@B14]). Hence, there is need for alternative animal models of AD.

Epidemiological studies have suggested a possible relationship between aluminum content in drinking water and AD ([@B36]; [@B1]; [@B20]; [@B19]; [@B17]). Workers exposed in aluminum industry have shown impaired cognitive functions ([@B48]; [@B44]; [@B21]). The activities of antioxidant enzymes like superoxide dismutase, catalase, and glutathione peroxidase are reduced, while xanthine oxidase is enhanced following exposure to aluminum chloride ([@B54]). Exposure to aluminum chloride leads to accumulation of intermediary toxic compounds such as hydrogen peroxide and hydroxyl radicals, which may mediate the aluminum toxicity. Excessive intake of aluminum causes overexpression of amyloid precursor protein, deposition of amyloids in the central nervous system, and impairment in learning and memory in rats ([@B6]). Aluminum has been shown to be colocalized with neurofibrillary tangles in AD patients. It induces degeneration of neurons in higher mammals ([@B9]). Most importantly, chronic aluminum exposure in mice leads to pathology similar to that observed in AD patients ([@B32]). Although, several studies on aluminum chloride neurotoxicity are available, its impact on neurotransmission and neurometabolism has not been studied in detail.

Traditional Ayurveda claims to facilitate 'healthy aging' ([@B16]), and thus has the possibility to alleviate the suffering from neurodegenerative disorders ([@B31]). Rasa Sindoor (RS), an organo-metallic derivative of mercury and sulfur, is used as part of the rejuvenating Rasayana therapy, and is believed to promote long life with enhanced physical and mental strength ([@B50]). RS was shown to improve general well-being of fruit flies. The dietary supplementation of RS prevented accumulation of inclusion bodies and heat shock proteins, improved the ubiquitin-proteasomal activity, suppressed apoptosis, elevated the levels of heterogeneous nuclear ribonucleoproteins and cyclic adenosine monophosphate response in Huntington and AD model in Drosophila ([@B16]). Therefore, we hypothesized that RS intervention will improve memory and energy metabolism in AD mammalian model also.

Glutamate and γ-aminobutyric acid (GABA) are the major excitatory and inhibitory neurotransmitters, respectively, in the mature mammalian central nervous system. ^13^C-NMR measurements carried out *in vivo* with infusion of ^13^C-labeled substrates have established that neurotransmitters, glutamate, and GABA, energetics is supported by oxidative glucose metabolism in healthy brain ([@B55]; [@B40]). In the current study, we employed ^1^H-\[^13^C\]-NMR spectroscopy in conjunction with infusion of \[1,6-^13^C~2~\]glucose in mice to investigate the energetics of glutamatergic and GABAergic neurotransmission in AlCl~3~ model of AD, and to evaluate the effects of RS intervention thereon. Our data suggest that exposure to AlCl~3~ adversely affected memory and metabolic activity of glutamatergic and GABAergic neurons in the hippocampus, cerebral cortex, and striatum. The RS intervention improved spatial memory and activity of excitatory and inhibitory neurons in AlCl~3~ treated mice.

Materials and Methods {#s1}
=====================

Animal Preparation
------------------

All animal experiments were performed under approved protocol by Animal Ethics Committee of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, and were conducted in accordance with the guidelines established by Committee for the Purpose of Control and Supervision on Experiments on Animals, Ministry of Environment and Forests, Government of India. Two-month-old C57BL/6J male mice were housed in the CCMB Animal House in a room maintained at ∼22-25°C with relative humidity of 55--65% and 12 h/12 h light/dark cycle, which switches ON and OFF at 6:00 am and 6:00 pm, respectively.

Administration of Aluminum Chloride and Rasa Sindoor (RS)
---------------------------------------------------------

Chronic exposure of AlCl~3~ in 2-month-old mice has been used to mimic the AD pathology in rodents ([@B66]; [@B12]). Mice were divided into two major sets of study. In the first set of study, animals were divided into two groups: **Ia**. Control (*n* = 12) and **Ib**. AlCl~3~ treated mice (*n* = 12) to assess the effects of Al exposure on memory and brain energy metabolism (**Figure [1](#F1){ref-type="fig"}**). Mice in Group **Ib** received AlCl~3~ (40 mg/kg) intraperitoneally once a day for 60 days, while Group **Ia** received normal saline (0.9% NaCl) for the same period (**Figure [2A](#F2){ref-type="fig"}** Group **I**). Aluminum chloride was purchased from Acros Organics. AlCl~3~ dissolved in normal saline (4 mg/ml) was administered (250 μl) to a 25-g mouse (40 mg/kg) between 1:00 and 2:00 pm once a day for 60 days.

![Schematic of ^13^C labeling of amino acids from \[1,6-^13^C~2~\]glucose. Metabolism of \[1,6-^13^C~2~\]glucose via glutamatergic and GABAergic TCA cycles labels \[4-^13^C\]glutamate, which is decarboxylated to \[2-^13^C\]GABA by GAD enzyme present specifically in GABAergic neurons. Labeling of \[4-^13^C\]glutamine occurs from \[4-^13^C\]glutamate and \[2-^13^C\]GABA via glutamate--glutamine and GABA--glutamine cycle. Further metabolism of \[4-^13^C\]glutamate and \[2-^13^C\]GABA in the corresponding TCA cycle incorporates label into \[2-^13^C\]/\[3-^13^C\]glutamate and \[3-^13^C\]/\[4-^13^C\]GABA, respectively. \[3-^13^C\]Pyruvate, the glycolytic product of \[1,6-^13^C~2~\]glucose is also metabolized by pyruvate carboxylase pathway (PC), and incorporates label into \[2-^13^C\]glutamine, \[2-^13^C\]glutamate, and \[4-^13^C\]GABA. For the simplicity, ^13^C labeling of amino acids from \[1,6-^13^C~2~\]glucose via the first turn of TCA cycle is depicted. Abbreviations used are: αKG, α-ketoglutarate; OAA, oxaloacetate; Asp, aspartate; GABA, γ-aminobutyric acid; Glu, glutamate; Gln, glutamine; V~cyc(GABA-Gln)~, GABA--glutamine cycling flux; V~cyc(Glu-Gln)~, glutamate--glutamine cycling flux; V~gad~, glutamate decarboxylase flux; V~gln~, glutamine synthesis rate; V~pc~, pyruvate carboxylase flux; V~shunt~, flux of GABA shunt; V~tca(A)~, Astroglial TCA cycle flux; V~tca(GABA)~, GABAergic TCA cycle flux; V~tca(Glu)~, glutamatergic TCA cycle flux; V~x~, exchange rate between α-ketoglutarate and glutamate. ^∗^Represents the position of ^13^C carbon.](fnmol-10-00323-g001){#F1}

![Schematic depiction of timeline of different treatments and measurements. **(AI)** Mice were administered AlCl~3~ (40 mg/kg, intraperitoneal) or normal saline once a day for 60 days. Mice were trained (61--64 day) and memory analysis (67^th^ day) was carried out using Morris Water Maze (MWM). Metabolic analysis was carried out on 69^th^ day by infusing \[1,6-^13^C~2~\]glucose, and measuring the labeling of amino acids in tissue extracts using ^1^H-\[^13^C\]-NMR spectroscopy. **(AII)** Mice were administered Rasa Sindoor (2 g/kg, intragastric) or CMC for 61 to 90 days following 60 days treatments of AlCl~3~ (40 mg/kg, intragastric) or normal saline. **(B)** Learning, and **(C)** Memory of mice following 60 days treatment of AlCl~3~ (40 mg/kg, intraperitoneal). Memory was assessed using Morris Water Maize test. **(D)** Immuno-histological depiction of Aβ plaques in AlCl~3~ treated mice. The arrows point to Aβ plaques in the AlCl~3~ treated mice.](fnmol-10-00323-g002){#F2}

In the second set of experiment, mice were divided into four subgroups: **IIa**. Control + Carboxy methyl cellulose, CMC (*n* = 7); **IIb**. AlCl~3~ + CMC (*n* = 6); **IIc**. Control + RS (*n* = 5); and **IId**. AlCl~3~ + RS (*n* = 5) to evaluate the effects of RS on memory and brain energy metabolism in AlCl~3~ exposed mice (**Figure [2A](#F2){ref-type="fig"}** Group **II**). Mice in Groups **IIb** and **IId** received AlCl~3~ (40 mg/kg, intragastrically) for 60 days, while those in **IIa** and **IIc** received normal saline for the same period. Following the 60 days of AlCl~3~ treatment, the Groups **IIc** and **IId** mice were administered RS in CMC (2 g/kg, intragastric) for 30 days, while Groups **IIa** and **IIb** received CMC. RS was procured from Arya Vaidya Sala, Kottakal, India. As per Ayurvedic Pharmacopeia of India, the shelf life of RS is infinite, since the HgS (Cinnabar) is known to be highly stable. For the present set of studies, we prepared a 20% suspension of RS in 1% CMC, and used within 2 days. All treatments of AlCl~3~ and RS in mice were carried out between 1:00 and 2:00 pm for the entire period of study.

Memory Assessment
-----------------

After 60 days of the AlCl~3~ treatment, memory of the mice was assessed using Morris Water Maze (MWM) test ([@B60]). The MWM consists of a circular pool with diameter and height, 120 and 47 cm, respectively, which was virtually divided into four equal quadrants. Different clues were provided on the wall of pool for spatial map of the environment. The pool was filled with water to a depth of 20 cm, and the water temperature was maintained between 22 and 25°C. An escape platform with 10 cm in diameter was submerged 0.5 cm under water level in the fourth quadrant. Mice were given 4 days of training, with four trials per day to locate the platform. Each training session was initiated from different quadrants and lasted for maximum period of 90 s. The time taken by mice (latency) to find the hidden platform was monitored with the help of Ethovision 3.1 software. The memory of mice was assessed on 7^th^ day by monitoring the time required by animals to reach the platform. Retention of memory in mice was assessed on 8^th^ day by removing the platform, and monitoring the time spent by animals in the platform zone. The learning and memory were also assessed following 30 days of RS intervention.

Infusion of \[1,6-^13^C~2~\]Glucose
-----------------------------------

Overnight fasted mice were anesthetized with urethane (1.5 g/kg, intraperitoneal). The body temperature of the animals was maintained at ∼37°C. The respiration rate of the animals was monitored using BIOPAC device (Santa Barbara, CA, United States). The tail vein was cannulated for infusion of ^13^C labeled substrate. \[1,6-^13^C~2~\]Glucose was purchased from ISOTEC, Miamiburg, United States, and dissolved (0.225 mol/L) in deionized water for infusion. \[1,6-^13^C~2~\]Glucose was administered as a bolus (1013 μmol/kg in 15 s), followed by an exponentially decreasing infusion rate every 0.5 min for the next 8 min, whereupon the rate was maintained to 51 μmol/kg/min until *in situ* freezing of the brain ([@B18]; [@B41]; [@B57]). Mice in Group I were administered \[1,6-^13^C~2~\]glucose for 10, 30, 60, and 90 min (*n* = 3 at each time point) to derive the ^13^C labeling kinetics of amino acids for metabolic analysis. Mice (*n* = 23) in second set of study were administered \[1,6-^13^C~2~\]glucose for 10 min (one time point) for estimation of metabolic flux using the initial rate approximation. Blood was collected from orbital sinus just before the end of the infusion, and the brain was frozen *in situ* in *liq.*N~2~ and stored at -80°C till further processing.

Extraction of Neurometabolites from Brain Tissue
------------------------------------------------

Brains were chiseled out and dissected into different regions such as cerebral cortex, hippocampus, and striatum under frozen conditions in a cryostat maintained at -20°C. Metabolites were extracted from frozen brain tissues ([@B42]). In brief, brain tissues were powdered with 0.1 mol/L HCl in methanol (1:2 w/v) using glass homogenizer maintained in a dry-ice-ethanol bath. \[2-^13^C\]Glycine (0.2 μmol, 99 atom%, Cambridge Isotopes, Andover, MA, United States) was added as a concentration reference. The powdered tissues were homogenized with ice-cold ethanol and centrifuged at 12,000 g for 30 min at 4°C to remove cell debris. The dried powder was dissolved in phosphate buffered deuterium oxide containing sodium trimethylsilylpropionate (0.25 mmol/L) for NMR analysis.

Analysis of Plasma Glucose
--------------------------

Blood plasma (100 μl) obtained from orbital sinus was mixed with deuterium oxide (450 μl) containing sodium formate (1 mmol/L), and passed through a centrifugal filter (10-kDa cutoff, VWR, Radnor, PA, United States) to remove macromolecules ([@B57]). Isotopic ^13^C labeling of glucose was determined in the plasma using ^1^H NMR spectroscopy at 600 MHz spectrometer. The concentration of glucose was determined from the area of glucose resonance (5.2 ppm) relative to formate. The percent ^13^C enrichment of glucose-C1 was calculated by dividing the area of the ^13^C-coupled satellites by the total ^1^H area (^12^C+^13^C) measured at 5.2 ppm.

NMR Spectroscopy of Brain Extracts
----------------------------------

^1^H-\[^13^C\]-NMR spectra of brain tissue extracts were recorded at 600 MHz NMR spectrometer (Bruker AVANCE II, Karlsruhe, Germany) using a triple resonance probe equipped with three axes gradients ([@B10]). NMR parameters used are as described in detail in [@B4]. In brief, a typical ^1^H-\[^13^C\]-NMR experiment involved collection of two spin-echo ^1^H NMR spectra under the condition of an OFF/ON ^13^C inversion pulse. Free induction decays (FIDs) were zero filled, apodized to Lorentzian line broadening, Fourier transformed, and phase corrected. The C-13 edited NMR spectrum was obtained by subtracting the spectrum obtained with ^13^C inversion pulse from that acquired under without inversion pulse. The concentrations of metabolites were calculated from the peak area in the spectrum obtained without ^13^C inversion pulse (OFF) relative to \[2-^13^C\]glycine. The isotopic ^13^C enrichments of amino acids at different carbon positions were determined from the ratio of area in the difference spectrum and the non-edited spectrum.

Estimation of Aluminum and Mercury in Brain
-------------------------------------------

The aluminum and mercury content in the cerebral cortex of the Group II mice was measured using inductively coupled plasma mass spectrometry (ICP-MS). In brief, the weighed amount of cerebral cortex was digested using plastic pestle in concentrated nitric acid (1 ml). The resulting homogenate was diluted to 10 ml, and analyzed by ICP-MS for aluminum and mercury content.

Immuno-Histochemical Analysis of Aβ Plaques in Brain
----------------------------------------------------

The Aβ plaques were visualized by immuno-staining in first set of experiment following 60 days of AlCl~3~ treatment. Bain samples were washed with phosphate buffered saline (PBS) followed by permeabilization with 0.1% Tween 20. The axial slices (30 μm) of brain were made using cryo-microtome, and stored in PBS with 0.1% sodium azide. For immuno-staining, sections were washed with PBS, blocked with 5% serum in PBS with 0.1% Tween 20, followed by overnight incubation at 4°C with primary Aβ antibody against the first 14 amino acids of the Aβ peptide (Abcam ab2539). The sections were washed thrice with PBS and treated with appropriate secondary antibody at 4°C for 1 h. The slides were washed again, mounted using Vectashield, and examined Confocal microscope (Leica SP5 AOBS) with a 10x dry objective.

Determination of Metabolic Rates from Kinetic Data
--------------------------------------------------

A three-compartment metabolic model ([@B41]; [@B57]) was fitted to the time courses of ^13^C labeling of amino acids from \[1,6-^13^C~2~\]glucose in the first set of study using a CWave software package ([@B35]) to determine the metabolic fluxes (**Figure [1](#F1){ref-type="fig"}**). The metabolic model consists of a series of differential equations describing mass balance and ^13^C isotope flowing from \[1,6-^13^C~2~\]glucose (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). The ^13^C turnover curves of \[3-^13^C\]glutamate, \[4-^13^C\]glutamate, \[2-^13^C\]GABA, \[3-^13^C\]GABA, \[3-^13^C\]aspartate and \[4-^13^C\]glutamine were used for the analysis. The averaged concentrations of glutamate, glutamine, GABA and aspartate measured (Supplementary Table [2](#SM1){ref-type="supplementary-material"}) in tissue extracts were used for metabolic modeling. Glutamine and GABA were assumed to be localized in astroglia and GABAergic neurons, respectively, whereas glutamate pool was distributed differently in brain regions as determined previously (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). The ratio V~cyc(Glu-Gln)~/V~tca(Glu)~ and V~cyc(GABA-Gln)~/V~tca(GABA)~ were constrained to values for the cerebral cortex, hippocampus and striatum as presented in Supplementary Table [1](#SM1){ref-type="supplementary-material"} ([@B57]). The values of V~dil(Gln)~, V~pc~, V~tca(ANet)~, V~dil(A)~, V~tca(GABANet)~, V~shunt~, V~dil(GABA)~, V~tca(Glu)~, V~dil(Glu)~ and V~xGlu(Glu-KG)~ were varied during modeling. The uncertainty in estimation of these parameters was determined using a Monte Carlo analysis as described previously by [@B34]. Briefly, 500 noisy data sets were generated by adding the random Gaussian noise to the noiseless set of data. The model was fitted to the data to generate a list of 500 values for each of the rates. These values were used to calculate average and standard deviation of each fitted parameters.

Estimation of Glucose Oxidation by Neurons
------------------------------------------

The rates of neuronal glucose oxidation in the second set of study were calculated based on the labeling of amino acids from 10-min infusion of \[1,6-^13^C~2~\]glucose as described earlier ([@B41]; [@B4]). The apparent cerebral metabolic rate of glucose oxidation (CMR~Glc(ox)~) by glutamatergic neurons was obtained as follows:
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where Glu~i~ and Asp~i~ are percentage ^13^C labeling of glutamate and aspartate, respectively, at carbon '*i'* from \[1,6-^13^C~2~\]glucose during 10-min infusion, Glc~1~ is the labeling of \[1-^13^C\]glucose in blood plasma, and \[Glu\] and \[Asp\] are the concentrations of glutamate and aspartate, respectively.

The cerebral metabolic rate of glucose oxidation by GABAergic neurons was estimated as follows:
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GABA~i~ is the percentage labeling of GABA at carbon *'i'* from \[1,6-^13^C~2~\]glucose, and \[GABA\] is the concentration of GABA in the cerebral cortex.

The total glucose oxidation was estimated as:
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Statistics
----------

The Student's *t*-test was applied to determine the significance of difference in the memory, concentration and metabolic rates in AlCl~3~ treated mice when compared with controls in the first set of study. One-way ANOVA was carried to determine the statistical significance of difference in the concentration, ^13^C labeling, and cerebral metabolic rate of glucose oxidation with RS intervention in the second set of study. The *post hoc* Tukey's honest test was carried out to further identify the statistical significance of difference among groups. All results are reported as mean ± standard error of the mean (SEM).

Results
=======

Effects of AlCl~3~ on Learning and Memory of Mice
-------------------------------------------------

The learning and memory of AlCl~3~ treated mice were assessed through the MWM test after 60 days of treatment and compared with parallel saline treated control mice. The escape latency, the time to locate the platform, is significantly longer (*p* = 0.031) on the 2^nd^ day of training in AlCl~3~ treated mice when compared with controls (**Figure [2B](#F2){ref-type="fig"}**). Additionally, AlCl~3~ treated mice (75.4 ± 6.1 s, *n* = 12) took significantly (*p* \< 0.002) longer time during memory test to reach the hidden platform when compared with normal saline treated controls (43.9 ± 7.8 s, *n* = 12) (**Figure [2C](#F2){ref-type="fig"}**). Moreover, these mice spent (22.8 ± 1.6 s, *n* = 12) significantly (*p* \< 0.001) less time in the platform zone than controls (34.4 ± 1.6 s, *n* = 12). These data suggest that AlCl~3~ exposure leads to impairment in the memory in mice.

Aluminum Content in Cortical Tissue
-----------------------------------

The level of aluminum in the cerebral cortex of control mice was found to be 3.4 ± 0.7 μg per gram of brain tissue (*n* = 5). The treatment of AlCl~3~ in mice for 2 months led to significant (*p* = 0.002) increase in aluminum content in AlCl~3~ treated animals (431.4 ± 129.3 μg per g of brain tissue, *n* = 5) (**Figure [3](#F3){ref-type="fig"}**). There was no significant (*p* = 0.90) difference for the aluminum content between AlCl~3~+RS and AlCl~3~+CMC group.

![The level of aluminum in the cerebral cortex of mice after 2 months AlCl~3~ treatment. The aluminum concentration was measured in brain homogenate using inductively coupled plasma mass spectrometry.](fnmol-10-00323-g003){#F3}

Effects of AlCl~3~ on Neurometabolites Homeostasis
--------------------------------------------------

The levels of neurometabolites were measured in non-edited ^1^H-\[^13^C\]-NMR spectrum of brain tissue extracts relative to \[2-^13^C\]glycine (**Figure [4A](#F4){ref-type="fig"}**). The levels of cortical neurometabolites remain unchanged (*p* \> 0.2) following 60 days exposure of AlCl~3~ (Supplementary Table [2](#SM1){ref-type="supplementary-material"}). The levels of glutamate and N-acetyl aspartate (NAA) were significantly (*p* \< 0.01) lower in the striatum in AlCl~3~ treated mice (*n* = 12) than in normal saline treated controls (*n* = 12). Moreover, a significant (*p* \< 0.001) increase in myo-inositol level was observed in hippocampus of the AlCl~3~ treated mice when compared with NS treated controls.

![Representative ^1^H-\[^13^C\]-NMR spectra from cortical tissue extracts of AlCl~3~ treated mice: **(A)**^1^H-\[^12^C+^13^C\] represents total concentration of metabolites, **(B)**^1^H-\[4x^13^C\] depicts ^13^C labeling of metabolites from \[1,6-^13^C~2~\]glucose. Mice were infused with \[1,6-^13^C~2~\]glucose for pre-defined time, and ^1^H-\[^13^C\]-NMR spectra were recorded from cortical tissue extracts. Peak labels are: Ala~C3~, alanine-C3; Asp~C3~, asparate-C3; GABA~C2~, GABA-C2; Gln~C4~, glutamine-C4; Glu~C4~, glutamate-C4.](fnmol-10-00323-g004){#F4}

Effects of AlCl~3~ on ^13^C Labeling of Brain Amino Acids from \[1,6-^13^C~2~\]Glucose
--------------------------------------------------------------------------------------

The cerebral metabolism was followed by ^1^H-\[^13^C\]-NMR spectroscopy in brain tissue extracts in conjunction with timed infusion of \[1,6-^13^C~2~\]glucose. The percent ^13^C labeling of plasma \[1-^13^C\]glucose averaged during entire period of infusion was found to be similar in AlCl~3~ treated mice (44.9 ± 5.7%, *n* = 12) and normal saline treated controls (40.8 ± 4.3%, *n* = 12), suggesting that AlCl~3~ did not perturb homeostasis of plasma glucose.

The ^13^C labeling of cortical amino acids was measured *ex vivo* in brain tissue extracts using ^1^H-\[^13^C\]-NMR spectroscopy. The ^13^C labeling of \[4-^13^C\]glutamate, \[3-^13^C\]alanine, and \[3-^13^C\]lactate was visible at 10-min infusion time in AlCl~3~ treated mice (**Figure [4B](#F4){ref-type="fig"}**). The labeling of different carbons of GABA, glutamine, and aspartate, which were very small at 10 min, could be seen from 30 min onward, and reached to steady state level by 60 min. A similar labeling pattern was observed in control mice. The percent ^13^C labeling of cortical metabolites at different carbon positions was calculated, and plotted with time to construct the ^13^C turnover curve of different amino acids from \[1,6-^13^C~2~\]glucose. A similar analysis was performed to generate the ^13^C turnover curves of amino acids in striatum and hippocampus.

Effects of AlCl~3~ Exposure on Metabolic Rates
----------------------------------------------

The metabolic rates associated with glutamatergic and GABAergic pathways were obtained by modeling of ^13^C labeling of amino acids from glucose. The best fit of the metabolic model (Supplementary Table [1](#SM1){ref-type="supplementary-material"}) to the ^13^C turnover of amino acids in the cerebral cortex is presented in **Figure [5](#F5){ref-type="fig"}**. Each symbol represents ^13^C labeling measured from individual animals (*n* = 12), while the line depicts the prediction of labeling based on metabolic model and optimum values of different iterated parameters. The quality of fit of the model to the ^13^C turnover of amino acids in the hippocampus and striatum was similar to that in the cerebral cortex.

![Fit of three compartment metabolic model to ^13^C turnover of cortical amino acids in **(A)** Control, **(B)** AlCl~3~ treated mice. Mice were infused with \[1,6-^13^C~2~\]glucose for pre-defined time. ^13^C Concentrations of cortical amino acids were measured in extracts in ^1^H-\[^13^C\]-NMR spectra. Symbols represent the measured ^13^C labeling, while lines show the best fit of the three compartment metabolic model.](fnmol-10-00323-g005){#F5}

### Cerebral Cortex

AlCl~3~ exposure considerably perturbed the metabolic activity in the cerebral cortex. The rate of neuronal glucose oxidation was found to be decreased by 30% in mice exposed to AlCl~3~ (0.252 ± 0.024 μmol/g/min) as compared with normal saline treated controls (0.362 ± 0.034 μmol/g/min; **Figure [6A](#F6){ref-type="fig"}**). The neurotransmitter cycling flux was also decreased to similar extent (Controls: 0.314 ± 0.035 μmol/g/min; AlCl~3~: 0.229 ± 0.026 μmol/g/min, *p* \< 0.001) with AlCl~3~ exposure (**Figure [6B](#F6){ref-type="fig"}**). Further analysis indicated that the reduction in TCA cycle flux of glutamatergic (0.405 ± 0.055 vs. 0.554 ± 0.076 μmol/g/min, *p* \< 0.001) and GABAergic neurons (0.166 ± 0.025 vs. 0.228 ± 0.042 μmol/g/min, *p* \< 0.001) together have contributed to metabolic deficit in AlCl~3~ treated mice (**Figures [6C,E](#F6){ref-type="fig"}**). Moreover, the rates of glutamate--glutamine and GABA--glutamine cycle were decreased with AlCl~3~ exposure (**Figures [6D,F](#F6){ref-type="fig"}**).

![Effects of AlCl~3~ treatment on **(A)** Neuronal metabolic rate of glucose oxidation, **(B)** Neurotransmitter cycling rates. **(C,E)** tricarboxylic acid cycle flux; **(D,F)** neurotransmitter cycling flux of glutamatergic **(C,D)** and GABAergic neurons **(E,F)**. Metabolic fluxes were obtained by analysis of ^13^C turnover of amino acids from \[1,6-^13^C~2~\]glucose using a three compartment metabolic model. The error in the rates was determined by performing the Monte-Carlo analysis. Values represent mean ± SEM. ^∗^*p* \< 0.001.](fnmol-10-00323-g006){#F6}

### Hippocampus

The impact of AlCl~3~ exposure in mice resulted in relatively smaller decrease in hippocampal metabolic rate as compared with that in the cerebral cortex (**Figures [6A,B](#F6){ref-type="fig"}**). The glutamatergic TCA cycle and glutamate--glutamine cycle fluxes were decreased in mice treated with AlCl~3~ (**Figures [6C,D](#F6){ref-type="fig"}**). The GABAergic TCA cycle (0.190 ± 0.031 vs. 0.239 ± 0.037 μmol/g/min, *p* \< 0.001) was found to be decreased significantly following AlCl~3~ exposure (**Figures [6E,F](#F6){ref-type="fig"}**).

### Striatum

The impact of AlCl~3~ exposure on striatal metabolic activity was in between the hippocampus and cerebral cortex. The rates of neuronal glucose oxidation (0.224 ± 0.019 vs. 0.285 ± 0.029 μmol/g/min, *p* \< 0.001) and neurotransmitter cycle (0.158 ± 0.019 vs. 0.183 ± 0.022 μmol/g/min, *p* \< 0.001) were reduced significantly with AlCl~3~ treatment (**Figures [6A,B](#F6){ref-type="fig"}**). The reduction in neuronal glucose oxidation and neurotransmitter cycle rates in striatum was mostly contributed by corresponding decrease in the glutamatergic TCA cycle (0.308 ± 0.047 vs. 0.379 ± 0.049 μmol/g/min, *p* \< 0.001) and glutamate--glutamine cycle (0.074 ± 0.011 vs. 0.091 ± 0.012 μmol/g/min, *p* \< 0.001). The relative changes in rates of GABAergic TCA cycle and neurotransmitter cycle were smaller in the striatum following AlCl~3~ exposure (**Figures [6E,F](#F6){ref-type="fig"}**).

These data suggest that exposure of AlCl~3~ for a period of two months has differential effect on glutamatergic and GABAergic metabolic activity across brain.

Cerebral Metabolism after One Month of AlCl~3~ Exposure
-------------------------------------------------------

The metabolic rate of glucose oxidation associated with different cell types in the cerebral cortex was reduced following AlCl~3~ exposure in Group II mice (**Figures [8B,C](#F8){ref-type="fig"}**). It is worth noting that the magnitude of reduction in CMR~Glc(ox)~ was higher (\>32%) in the hippocampal and striatal regions following a waiting of one month as compared with that measured immediately in first set of study. The impact of one month waiting period was relatively more on the metabolic activity of GABAergic neurons in the striatum, which reduced by 28% as compared with only 8% reduction immediately after AlCl~3~ treatment. The glutamatergic rate that was decreased by 19% immediately after AlCl~3~ exposure was found to be reduced by 33% after one month of waiting period. The most dramatic effects of one month waiting period was observed in hippocampal region, wherein metabolic deficit was found in the range of 34--49% (Group II mice), while it was only 14--20% in the first set of experiment measured immediately after AlCl~3~ exposure.

RS Intervention Improves Memory in AlCl~3~ Treated Mice
-------------------------------------------------------

A test for the retention of memory without platform indicated that the time spent around the platform area is significantly (*p* = 0.001) less in AlCl~3~ exposed mice. Intervention of RS to AlCl~3~ treated mice for one month period was found to decrease the escape latency (28.1 ± 5.1 s, *n* = 7) significantly (*p* = 0.001*)* as compared with the vehicle (CMC) treated AlCl~3~ mice (82.6 ± 7.4 s, *n* = 5). Furthermore, analysis of retention of memory indicated that time spent around the platform zone is also increased significantly (*p* = 0.04) following RS administration (AlCl~3~+CMC 20.0 ± 1.9 s, *n* = 5; AlCl~3~+RS 29.7 ± 1.4 s, *n* = 6, **Figure [7B](#F7){ref-type="fig"}**). It is noteworthy that RS intervention in control mice had no significant effect on the escape latency (*p* = 0.71) (**Figure [7A](#F7){ref-type="fig"}**) or on the time spent around the platform (*p* = 0.58). Although the average latency to reach the platform appears to be higher in Control+RS mice than AlCl~3~+RS group, the difference is not significant (*p* = 0.069). Moreover, the latency of Control+RS mice (54.0 ± 8.6 s) was not significantly (*p* = 0.71) different from Control+CMC (42.7 ± 9.0 s).

![**(A)** Learning, and **(B)** Memory of mice following Rasa Sindoor (RS) intervention. Mice were administered RS (2 g/kg, intragastric) for 61--90 days following 60 days treatments of AlCl~3~ (40 mg/kg, intragastric). The memory was assessed using Morris Water Maze. The statistical analysis suggested no significant (*F*\[3,32\] ≤ 2.359, *p* ≥ 0.09) difference in learning among different groups of mice.](fnmol-10-00323-g007){#F7}

There was no significant (*p* = 0.90) difference for the aluminum content between AlCl~3~+RS and AlCl~3~+CMC group (**Figure [3](#F3){ref-type="fig"}**). Moreover, the analysis of mercury indicated no significant increase in mercury level in RS treated mice (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). These data suggest that RS intervention has improved memory in AlCl~3~ exposed mice without any adverse effect on memory in controls.

RS Intervention Improved Brain Energy Metabolism in AlCl~3~ Treated Mice
------------------------------------------------------------------------

As mentioned above, the ^13^C labeling of cortical \[4-^13^C\]glutamate (*p* = 0.049), \[3-^13^C\]glutamate (*p* = 0.001), \[3-^13^C\]aspartate (*p* = 0.001), and \[4-^13^C\]glutamine (*p* = 0.009) was found to be reduced significantly in AlCl~3~ treated mice as compared with the normal saline treated controls (**Table [1](#T1){ref-type="table"}**). The RS intervention in AlCl~3~ exposed mice increased ^13^C labeling of cortical \[4-^13^C\]glutamate (AlCl~3~+CMC 1.61 ± 0.05, *n* = 5; AlCl~3~+RS 1.91 ± 0.05 μmol/g, *n* = 7, *p* = 0.057) and \[3-^13^C\]aspartate (AlCl~3~+CMC 0.12 ± 0.01, *n* = 5; AlCl~3~+RS 0.17 ± 0.01 μmol/g, *n* = 7, *p* = 0.034) when compared with CMC treated mice (**Table [1](#T1){ref-type="table"}** and Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). Though, the ^13^C labeling of \[4-^13^C\]glutamine was increased with RS supplementation in AlCl~3~ treated mice (AlCl~3~+CMC 0.19 ± 0.01, *n* = 5; AlCl~3~+RS 0.25 ± 0.02, *n* = 7, μmol/g), it did not reach to statistical significance (*p* = 0.067). In addition to improvement in the ^13^C labeling of these amino acids, a robust increase in the labeling of \[2-^13^C\]GABA, \[3-^13^C\]aspartate, and \[4-^13^C\]glutamine in the subcortical regions, namely hippocampus and striatum, was observed (**Table [1](#T1){ref-type="table"}**). It is worth noting that RS did not affect the ^13^C labeling of amino acids in control mice (*p* \> 0.20).

###### 

Concentration (μmol/g) of ^13^C labeled amino acids from \[1,6-^13^C~2~\]Glucose in RS-treated mice.

  Brain region      Treatment group   Amino acids                                                                                 
  ----------------- ----------------- ----------------- ----------------- ----------------- ------------------- ----------------- -----------------
  Cerebral Cortex   Control+CMC       1.97 ± 0.09       0.21 ± 0.02       0.29 ± 0.02       0.20 ± 0.02         0.42 ± 0.07       0.08 ± 0.02
                    Control+RS        1.99 ± 0.13       0.20 ± 0.01       0.25 ± 0.01       0.17 ± 0.01         0.32 ± 0.02       0.05 ± 0.01
                    AlCl~3~+CMC       1.61 ± 0.06^∗^    0.16 ± 0.01       0.19 ± 0.01^∗∗^   0.12 ± 0.01^∗∗^     0.23 ± 0.02^∗∗^   0.04 ± 0.01
                    AlCl~3~+RS        1.91 ± 0.05       0.21 ± 0.01       0.25 ± 0.02       0.17 ± 0.01^\#^     0.29 ± 0.01       0.05 ± 0.01
  Hippocampus       Control+CMC       1.67 ± 0.07       0.31 ± 0.02       0.25 ± 0.02       0.17 ± 0.01         0.34 ± 0.05       0.09 ± 0.01
                    Control+RS        1.64 ± 0.08       0.29 ± 0.02       0.23 ± 0.01       0.14 ± 0.01         0.27 ± 0.02       0.08 ± 0.01
                    AlCl~3~+CMC       1.24 ± 0.06^∗∗^   0.19 ± 0.01^∗∗^   0.16 ± 0.01^∗∗^   0.10 ± 0.01^∗∗^     0.17 ± 0.02^∗∗^   0.04 ± 0.01^∗∗^
                    AlCl~3~+RS        1.61 ± 0.09^\#^   0.27 ± 0.01^\#^   0.24 ± 0.02^\#^   0.16 ± 0.02^\#\#^   0.28 ± 0.04^\#^   0.08 ± 0.01^\#^
  Striatum          Control+CMC       1.34 ± 0.11       0.22 ± 0.02       0.18 ± 0.02       0.12 ± 0.01         0.30 ± 0.03       0.07 ± 0.02
                    Control+RS        1.29 ± 0.06       0.19 ± 0.01       0.17 ± 0.01       0.12 ± 0.01         0.22 ± 0.02       0.05 ± 0.01
                    AlCl~3~+CMC       0.86 ± 0.06^∗∗^   0.14 ± 0.01^∗∗^   0.11 ± 0.01^∗∗^   0.06 ± 0.01^∗^      0.11 ± 0.02^∗∗^   0.04 ± 0.01
                    AlCl~3~+RS        1.20 ± 0.07^\#^   0.18 ± 0.01       0.15 ± 0.01       0.11 ± 0.02         0.21 ± 0.02^\#^   0.05 ± 0.01
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The cerebral metabolic rates of glucose oxidation in the second set of study, calculated using Equations 1--3, are presented in **Figure [8](#F8){ref-type="fig"}**. The RS intervention improved the rate of glucose oxidation in the cerebral cortex (AlCl~3~+CMC 0.270 ± 0.011, *n* = 5; AlCl~3~+RS 0.341 ± 0.011, μmol/g/min, *n* = 7, *p* = 0.028) in AlCl~3~ exposed mice. Analysis of energy metabolism at the cellular level revealed that recovery of CMR~Glc~ in glutamatergic neurons (AlCl~3~+CMC 0.180 ± 0.006, *n* = 5; AlCl~3~+RS 0.219 ± 0.007, μmol/g/min, *n* = 7, *p* = 0.044) was better than that in GABAergic neurons (*p* = 0.07). It is noteworthy that RS intervention did not affect (*p* \> 0.3) the cortical glucose oxidation in control mice. The improvement in energy metabolism with RS intervention was relatively higher in the subcortical regions (∼40--70%; striatum and hippocampus) as compared with that in the cerebral cortex (∼20--30%) of AlCl~3~ treated mice. These data indicate beneficial effect of RS on the energy metabolism of neurons in AlCl~3~ treated mice.

![Effects of Rasa-sindoor intervention on cerebral metabolic rates of glucose oxidation (CMR~Glc(ox)~): **(A)** Total, **(B)** Glutamatergic Neurons, and **(C)** GABAergic neurons in the cerebral cortex, hippocampus and striatum in AlCl~3~ treated mice. Mice were infused with \[1,6-^13^C~2~\]glucose for 10 min. The CMR~Glc(ox)~ was calculated based on the ^13^C labeled trapped into different amino acids using Equations 1--3 as described in the Methods section. Values are presented as mean ± SEM. ^∗^*p* = 0.01, ^∗∗^*p* = 0.001. The number of mice used in different groups were: Control + CMC (*n* = 7); Control + RS (*n* = 5); AlCl~3~ + CMC (*n* = 6) and AlCl~3~ + RS (*n* = 5).](fnmol-10-00323-g008){#F8}

Discussion
==========

Although brain energy metabolism has been studied extensively in qualitative manner but its quantitative significance is not much explored in AD. In the present study, we evaluated the excitatory and inhibitory neuronal activity in several brain regions like cerebral cortex, hippocampus, and striatum in the AlCl~3~ model of AD. AlCl~3~ at doses ranging from 1 to 500 mg/kg has been used in different studies in animals to mimic AD physiology ([@B61]; [@B7]). The dose of AlCl~3~ (40 mg/kg) used in the current study is in the intermediate range of that used in a previous study ([@B54]). In addition, effects of RS, an Ayurvedic formulation, on the brain energy metabolism in AlCl~3~ model of AD was examined.

Chronic administration of aluminum chloride in rodent has been used to model the AD in animals. Exposure of AlCl~3~ (50 mg/kg) to albino mice for 3 months period showed significant impairment of spatial working memory as compared with controls ([@B47]). In a more recent study, in addition to reduced working memory, a significant accumulation of Aβ plaques in the cerebral cortex and hippocampus of mice exposed to AlCl~3~ was also shown ([@B7]). In the present study, we have administered AlCl~3~ (40 mg/kg) intraperitoneally for 60 days, and memory and cerebral metabolism were assessed on 67^th^ day or latter (**Figure [2A](#F2){ref-type="fig"}** Group **I**). These animals showed significant reduction in the memory and neurometabolic activity. Moreover, immuno-histochemical analysis exhibited presence of small Aβ plaques in the cerebral cortex and hippocampus of the AlCl~3~ treated mice. In the second set of experiments, AlCl~3~ (40 mg/kg) was administered orally to mice for 60 days, and behavioral and metabolic analysis were undertaken beyond 97^th^ day, i.e., ∼35 days after the last treatment of AlCl~3~ (**Figure [2A](#F2){ref-type="fig"}** Group **II**). As shown in **Figures [7B](#F7){ref-type="fig"}** and **[8](#F8){ref-type="fig"}**, these mice showed impairment in memory and metabolic activity. It should be noted that a waiting period of 35 days further deteriorated neurometabolic activity in AlCl~3~ mice. These data suggest that impact of AlCl~3~ on memory and cerebral metabolic activity lasted at least ∼5--6 weeks of AlCl~3~ withdrawal. However, the long-term effect of AlCl~3~ withdrawal on memory and metabolic function need further investigation.

Measurements of levels of brain metabolites in AD patients using ^1^H Magnetic Resonance Spectroscopy have indicated a decrease in levels of NAA ([@B28]) and glutamate ([@B25]), and an increase in myo-inositol level ([@B2]; [@B63]; [@B22]). The decrease in NAA level has been attributed with neuronal death and reduced viability of neurons, while the increased level of myo-inositol is associated with astrogliosis. Significant increase in the level of myo-inositol and reduction in the levels of glutamate and NAA, a neuronal marker, have been reported in AβPP-PS1 mice beyond 12 months of age ([@B33]). AβPP-PS1 mice display sparse plaque loading and unperturbed neurometabolites homeostasis at the age of 6 months that represents preclinical stage of AD ([@B26]). We did not find any significant change in the level of neurometabolites the cerebral cortex and hippocampus of AlCl~3~ treated mice. However, a significant reduction in the level of glutamate and NAA was observed in the striatum of AlCl~3~ treated mice. Our findings of unperturbed neurometabolites homeostasis in the cerebral cortex and hippocampus suggest that AlCl~3~ treated mice might represent preclinical stage of AD. Furthermore, the finding of increased level of myo-inositol is suggestive of enhanced astroglial activity in the hippocampus of AlCl~3~ exposed mice.

Cerebral glucose metabolism has been evaluated using positron emission tomography in AD patients. Hypo-glucose metabolism has been reported in patients at the various stages of AD or even before the appearance of clinical symptoms ([@B13]; [@B30]). In consistence with these observations, decreased TCA cycle flux for glutamatergic and GABAergic neurons was reported in the frontal cortex and hippocampal formation of transgenic McGill-R-Thy1-APP rat model of AD ([@B37]). The reduction in brain energy metabolism was also observed at the age of 13 months in a triple transgenic mouse harboring APP(Swe), PS1(M146V), and Tau(P301L) transgenes ([@B49]). Moreover, impaired glutamatergic and GABAergic metabolic activity has been observed in the cerebral cortex, hippocampus, and striatum even at the age of 6 months in AβPP-PS1 mice ([@B58]). The data from the current study indicate that AlCl~3~ treatment in mice exhibit reduction in energy metabolism of glutamatergic (15--27%) and GABAergic neurons (8--27%) across brain (**Figure [6](#F6){ref-type="fig"}**). Furthermore, analysis carried out one month after AlCl~3~ treatment indicated severe metabolic deficit in glutamatergic (18--34%) and GABAergic (24--49%) neurons across brain (**Figure [8](#F8){ref-type="fig"}**). These data suggest the AlCl~3~ affects the neuronal metabolic activity in time-dependent manner. As there was no significant perturbation in the level of glutamate, GABA, and NAA in the cerebral cortex and hippocampus, these mice resemble to the preclinical stage of AD.

Neurons and astrocytes work in a concerted manner to bring about optimal neurotransmitter cycling and functioning of the brain. Perturbation in the flux through glutamate and GABA neurotransmitter pathways is associated with several psychiatric and neurological conditions. ^13^C NMR spectroscopy together with infusion of \[1,6-^13^C~2~\]glucose provides a unique approach for monitoring neuronal activity under different pathological conditions ([@B40]) and during interventions ([@B4]; [@B49]). The trafficking of neurotransmitters amino acids between neurons and astrocytes, commonly referred as neurotransmitter cycling, plays important role in the normal functioning of brain. As per our knowledge, there is no quantitative information for the neurotransmitter flux in AD patients. Qualitative analysis of ^13^C label incorporation into \[4-^13^C\]glutamine from \[1-^13^C\]glucose in the transgenic mouse model suggested perturbation in glutamate--glutamine cycling in AD condition ([@B37]). A very recent study conducted using double transgenic AβPP-PS1 mice has indicated severe reduction in excitatory and inhibitory neuronal metabolic activity and neurotransmitter cycling fluxes, and increased astroglial metabolic activity across brain ([@B43]). The quantitative analysis of neurotransmitter cycling flux in the current study indicated that exposure of AlCl~3~ decreased the trafficking of neurotransmitter between neurons and astrocytes (**Figure [6B](#F6){ref-type="fig"}**) in the cerebral cortex (27%), hippocampus (16%), and striatum (14%). The decrease in neurotransmitter cycling flux in the cerebral cortex and hippocampus was contributed by deficit in both glutamate--glutamine and GABA--glutamine cycle, while it was mostly due to glutamate--glutamine cycling in striatum (**Figures [6D,F](#F6){ref-type="fig"}**). Hence, the preclinical stage of AD is manifested by reduced excitatory and inhibitory activity in the cerebral cortex and hippocampus, and selective reduction in excitatory function in the striatum. The cerebral cortex plays an important role in higher order cognition, while the hippocampus is involved in the learning and memory. The reduced neuronal activity in the cerebral cortex and hippocampus in AlCl~3~ exposed mice point toward impairment of cognitive function and memory at preclinical stage of AD.

The treatment strategies for AD have focused on decreasing the load of β-amyloid by inhibition of β-/γ-secretases and Aβ oligomerization; activation of proteases, α-secretase, and immunotherapy ([@B3]; [@B8]; [@B23]). Although different approaches have been used to combat AD, there is very limited success for the treatment of the disease. Donepezil, an acetylcholine esterase inhibitor, is the first line FDA approved drug for the palliative treatment of AD. It is used to improve cognitive function in AD patients but does not slow the progression of the disease. Hence, there is an increased effort for screening of traditional formulations for the treatments of AD.

In recent time, interest in using plant products and other traditional therapies for alleviation of symptoms of AD in animal models and human patients has increased. Preparation based on different plants such as *Amalaki Rasayana* ([@B59]), *Withania somnifera* ([@B51]), *Centellaasiatica* ([@B11]), *Huperzine A* ([@B64]), *Gingko biloba* ([@B39]), *Curcumin* ([@B62]), and *Melissa officinalis* ([@B27]) have been shown to reduce dementia with lesser side effects than conventional drugs, and therefore, regarded as potential anti-AD drugs ([@B56]). Extract of the roots of *Withania somnifera* was shown to reverse the accumulation of β-amyloid peptides (Aβ) and oligomers, and plaque pathology in the young and middle age of AβPP-PS1 transgenic mouse model of AD ([@B51]). The protective effect of RS has been examined in *GMR-Aβ42 Drosophila* model of AD. The transgenic *Drosophila* larvae reared on RS supplemented food exhibited substantial reduction in the damage to eye disk, and amyloid Aβ plaques compared to those reared on normal food ([@B16]). This suggests that RS has the potential to ameliorate AD condition by reducing Aβ plaques. Although Aβ plaque load has not been examined in the RS treated AlCl~3~ mice in the current study, it is presumed that a similar mechanism may be operating in mice also, which may be examined in further studies. Our data suggest that intervention with RS completely restores the memory of mice exposed to AlCl~3~. Most interestingly, RS intervention resulted in improved functionality of neuronal cells as revealed by the cerebral metabolic rate of neuronal glucose oxidation. The metabolic activity of glutamatergic and GABAergic neurons that was impaired drastically in AlCl~3~ treated mice was restored very close to control levels across the brain. The neuronal glucose oxidation and neurotransmitter cycling flux have been shown to be stoichiometrically coupled ([@B55]; [@B40]). Hence, the finding of increased neuronal glucose oxidation with RS intervention in AlCl~3~ treated mice is suggestive of increased glutamate--glutamine and GABA--glutamine neurotransmitter cycling flux with RS treatments.

A common objection against metal-derived Ayurvedic formulations is their potential toxicity ([@B38]). In this context, it is significant to note that as reported earlier ([@B15]; [@B46]), we did not find any evidence for toxicity resulting from RS administration to control mice (**Figure [8](#F8){ref-type="fig"}**). Moreover, analysis of mercury indicated no significant (F\[2,9\] = 0.27, *p* = 0.77) change in mercury level in RS treated mice (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). The control group of mice did not suffer any negative consequences, while the experimental group showed positive improvement in memory functions and brain energy metabolism.

Limitations
===========

There are a few potential limitations of the study. The first among them is the use of ratio of neurotransmitter cycling to the tri-carboxylic acid cycle (V~cyc~/V~TCA~) for glutamatergic and GABAergic neurons for the constraint during model fitting to previously reported value ([@B57]). In the current study, we have used the ratio (V~cyc~/V~TCA~) that was obtained in normal mice ([@B57]). These values have potential to be altered following AlCl~3~ exposure in mice, and hence the flux of neurotransmitter cycling and TCA cycle of glutamatergic and GABAergic neurons. Previous analysis has indicated that a 50% reduction in the value of ratio of neurotransmitter cycling to TCA cycle rate decreased the TCA cycle and neurotransmitter cycling at most by 7%, while an increase in the ratio results in 14% higher metabolic rates ([@B63]). Therefore, we believe that even if AlCl~3~ neurotoxicity changes the V~cyc~/V~tca~ ratio, it will not have much impact on the conclusion of the study. The ratio of neurotransmitter cycle to neuronal TCA cycle flux could be pinned down more accurately by using a steady state infusion of \[2-^13^C\]acetate, respectively ([@B41]; [@B57]).

Metabolic rates in the second set of study are based on the trapping of ^13^C label in different neurometabolites such as glutamate, GABA and aspartate, using Equations 1--3. This approach does not account for the flow of label into glutamine-C4 via neurotransmitter cycling. Moreover, ^13^C label lost as CO~2~, and shuttled into lactate-C3 and alanine-C3 were not accounted. Hence, the cerebral metabolic rates of glucose oxidation derived using Equations 1--3 will be underestimated. However, it may be argued that underestimates in metabolic rates would be of similar degrees in the different groups. Hence, the relative values, and direction of the changes in their respective CMR~Glc~ would remain the same, and thus not have much impact on the findings. More accurate estimates of cerebral metabolic rates of glucose oxidation by GABAergic and glutamatergic neuronal TCA and neurotransmitter cycles could be obtained by modeling of ^13^C turnover of amino acids from \[1,6-^13^C~2~\]glucose as described for the first set of experiment.

Conclusion
==========

Exposure of AlCl~3~ results in perturbation in neurometabolism across brain without severely affecting the homeostasis of neurometabolites in the cerebral cortex and hippocampus, an observation similar to preclinical stage in AβPP-PS1 mice ([@B58]). Hence, AlCl~3~ exposure paradigm may be useful to model preclinical stage of AD. Our finding that intervention with RS improved memory and neuronal metabolism in AlCl~3~ treated mice indicates that RS may be useful for the management of memory and cognitive functions in preclinical stage of AD.
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